Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

Home
/
update
/
details

Naveris Showcases Groundbreaking Data on NavDx® Test for HPV-Driven Cancers at ASTRO 2024

NextEdge Admin

29 Sep 2024

2 min 20 sec

ASTRO 2024,precision oncology diagnostics,HPV DNA

Naveris, Inc., a leader in precision oncology diagnostics for viral-induced cancers, is presenting new data at the 66th Annual Meeting of the American Society for Radiation Oncology (ASTRO) from September 29 to October 2, 2024, in Washington, D.C. The presentations will highlight the role of the NavDx® test, the first clinically validated circulating Tumor Tissue Modified Viral (TTMV®)-HPV DNA blood test, in managing HPV-driven oropharyngeal cancers and its integration into radiation oncology practices.

Dr. Barry M. Berger, Naveris' Chief Medical Officer, emphasized that ASTRO provides an ideal platform to demonstrate how the NavDx test personalizes treatment, improves real-time surveillance, and enhances patient outcomes.

Key presentations include:

1. **Oral Presentation:** On October 1, 2024, from 4:40 PM – 4:50 PM EDT, MD Anderson researchers will discuss how NavDx can identify treatment failure risks earlier than imaging in a Phase III trial of chemoradiation with proton therapy for HPV+ oropharyngeal squamous cell carcinoma.

2. **Educational Session:** On September 30, 2024, experts from the University of Pennsylvania, Mayo Clinic, University of Michigan, and Mass General Brigham will discuss integrating HPV ctDNA testing into clinical practice for HPV+ oropharyngeal cancer.

3. **Poster Presentations:** Studies from The Ohio State University, University of Virginia, and Emory University will show how NavDx predicts treatment outcomes, guides early cessation of radiotherapy, and surpasses imaging in post-radiotherapy surveillance.

Naveris will exhibit at Booth #2037, showcasing NavDx’s impact on improving care in HPV-driven cancers.